Global Renal Denervation (RDN) Therapy Market Growth (Status and Outlook) 2023-2029

Global Renal Denervation (RDN) Therapy Market Growth (Status and Outlook) 2023-2029

The global Renal Denervation (RDN) Therapy market size is projected to grow from US$ 917.1 million in 2022 to US$ 8635.3 million in 2029; it is expected to grow at a CAGR of 37.8% from 2023 to 2029.

United States market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Renal Denervation (RDN) Therapy players cover Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Ltd, Bio-Heart, SyMap Medical, Venus Medtech and Shanghai Microport Ep Medtech Co.,Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Renal Denervation (RDN) Therapy Industry Forecast” looks at past sales and reviews total world Renal Denervation (RDN) Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Renal Denervation (RDN) Therapy sales for 2023 through 2029. With Renal Denervation (RDN) Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Renal Denervation (RDN) Therapy industry.

This Insight Report provides a comprehensive analysis of the global Renal Denervation (RDN) Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Renal Denervation (RDN) Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Renal Denervation (RDN) Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renal Denervation (RDN) Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renal Denervation (RDN) Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Renal Denervation (RDN) Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Radio Frequency
Ultrasonic

Segmentation by application
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medtronic (Covidien)
ReCor
Johnson & Johnson
Boston Scientific
Shanghai Golden Leaf Med Tec Co., Ltd
Bio-Heart
SyMap Medical
Venus Medtech
Shanghai Microport Ep Medtech Co.,Ltd.
Cryofocus Medtech



Please note: The report will take approximately 2 business days to prepare and deliver.